RIM-based value premium and factor pricing using value-price divergence

被引:5
|
作者
Cong, Lin William [1 ,2 ]
George, Nathan Darden [3 ]
Wang, Guojun [4 ]
机构
[1] Cornell Univ, Samuel Curtis Johnson Grad Sch Management, Ithaca, NY USA
[2] Natl Bur Econ Res NBER, Cambridge, MA USA
[3] Univ Calif Berkeley, Haas Sch Business, Berkeley, CA USA
[4] Shanghai Normal Univ, Sch Finance & Business, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Asset pricing; Factor models; Mispricing; RIM; Value Investing; CROSS-SECTION; STOCK; VALUATION; RISK; MOMENTUM; RETURNS; ANOMALIES; COSTS;
D O I
10.1016/j.jbankfin.2023.106812
中图分类号
F8 [财政、金融];
学科分类号
0202 ;
摘要
We document that value-to-price, the ratio of Residual-Income-Model-based valuation to market price, subsumes the power of book-to-market ratio and many other value or quality measures in predicting stock returns. Long-short value-to-price portfolios hedge against momentum, revitalize the seemingly missing value premium over past decades, and generate significant returns after adjusting for common factors. The value-price-divergence (VPD) factor constructed from the average returns of these portfolios within small and big stocks is not spanned by these known factors. Max Sharpe ratio and constrained R-squared tests reveal that VPD is a better substitute for the traditional value factor and that a four-factor model using the VPD, market, momentum, and size factors outperforms most extant benchmarks in ex-plaining the cross-section of expected equity returns, including value-to-price portfolios as test assets. The findings remain robust under alternative specifications of equity cost of capital.(c) 2023 Elsevier B.V. All rights reserved.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] Implementation of Value-based Pricing for Medicines
    Jommi, Claudio
    Armeni, Patrizio
    Costa, Francesco
    Bertolani, Arianna
    Otto, Monica
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 15 - 24
  • [32] Defining Value-Based Pricing of Drugs
    Broder, Michael S.
    Ortendahl, Jesse D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (16): : 1710 - 1710
  • [33] MODELING AND ANALYTICS FRAMEWORK FOR VALUE BASED PRICING
    Dinh, T.
    Newton, M.
    VALUE IN HEALTH, 2013, 16 (03) : A54 - A54
  • [34] Value-based pricing of drugs in the UK
    Webb, David J.
    Walker, Andrew
    LANCET, 2007, 369 (9571): : 1415 - 1416
  • [35] Shapley value based pricing for auctions and exchanges
    Lindsay, Luke
    GAMES AND ECONOMIC BEHAVIOR, 2018, 108 : 170 - 181
  • [36] Value-based pricing for medical education?
    Walsh, Kieran
    PAN AFRICAN MEDICAL JOURNAL, 2013, 16
  • [37] SUSTAINABLE HEALTH CARE SYSTEMS: THE ROLE OF THERAPEUTIC VALUE AND VALUE BASED PRICING
    Hulshof, J. A. M.
    VALUE IN HEALTH, 2014, 17 (07) : A452 - A452
  • [38] Capturing the value premium - global evidence from a fair value-based investment strategy
    Woltering, Rene-Ojas
    Weis, Christian
    Schindler, Felix
    Sebastian, Steffen
    JOURNAL OF BANKING & FINANCE, 2018, 86 : 53 - 69
  • [39] COMPARING FACTORS INFLUENCING PRICE ELASTICITY OF PHARMACEUTICALS AND VALUE-BASED PRICING ACROSS EUROPE AND THE USA
    James, M.
    Sinha, A.
    Pannu, K.
    Grant, H.
    Jones, C.
    Foy, C.
    VALUE IN HEALTH, 2024, 27 (12)
  • [40] Value-based pricing in competitive situations with the help of multi-product price response maps
    Dost, Florian
    Geiger, Ingmar
    JOURNAL OF BUSINESS RESEARCH, 2017, 76 : 219 - 236